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ABSTRACT
Objective To ascertain possible determinants of carbamazepine (CBZ) and
oxcarbazepine (OXC) induced hyponatremia in a large cohort of people with
epilepsy.
Methods We collected data on serum sodium levels in people with epilepsy
attending a tertiary epilepsy centre while on treatment with CBZ or OXC. We defined
hyponatremia as Na+≤134 mEq/L and severe hyponatremia as Na+≤128 mEq/L. 
Results We identified 1,782 people who had used CBZ (n=1,424) or OXC (n=358) of
whom 50 were treated with both drugs. Data on sodium level measurements were
available in 1,132 on CBZ and in 289 on OXC. Hyponatremia occurred in 26% of
those taking CBZ and 46% taking OXC. This was severe in 7% in the CBZ group and
22% in the OXC group. Hyponatremia was symptomatic in 48% and lead to
admissions in 3%. Age over 40 years, high serum levels of CBZ and OXC and
concomitant use of other antiepileptic drugs were the main risk factors for
hyponatremia in both treatment groups. Females on OXC were at a higher risk of
hyponatremia than males. The risk of hyponatremia on CBZ was significantly
associated with the risk of hyponatremia on OXC within a subgroup that used both
drugs consecutively.
Significance Hyponatremia is a common problem in people taking CBZ or OXC.
Regular ascertainment of sodium levels in those taking either drug is recommended
and results should be acted upon.
Keywords: Antiepileptic drugs, sodium levels, adverse effects, electrolytes.
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INTRODUCTION
The antiepileptic drugs (AEDs) carbamazepine (CBZ) and its keto-analogue
oxcarbazepine (OXC) are among the drugs of choice for the treatment of focal
epilepsy. The use of CBZ and OXC is limited by hyponatremia. It can lead to
symptoms ranging from unsteadiness and mild confusion to seizures and coma
although it is often assumed to be asymptomatic.1,2 Its severity depends on the
absolute sodium levels and the rate of decline of sodium.3 The reported prevalence
of CBZ and OXC induced hyponatremia (COIH) varies greatly; for CBZ the reported
estimates are between 4 and 40% whilst for OXC they are between 23 and 73%.4,5
Data on risk factors for hyponatremia are limited. A few studies have looked at sex,
age, dose and use of other AEDs, but results were inconclusive, often due to low
sample size.
We aimed to confirm previous observations, evaluate the clinical characteristics of
hyponatremic and identify possible determinants of COIH in a large cohort of people
treated for epilepsy.
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METHODS
An electronic database designed for pharmacogenomics studies (www.epipgx.eu),
capturing all relevant clinical data with an emphasis on AED history, has been in use
since 2010 at a tertiary referral centre for epilepsy (http://www.sein.nl/en/). It was
used to identify all individuals who were prescribed CBZ or OXC and who had a
recorded serum sodium level during therapy. Levels were measured during the
course of routine monitoring. For each sodium level measurement, we recorded the
date, serum level of CBZ or OXC and concomitant use of other AEDs. Most
individuals had several measurements and we used the lowest sodium level recorded
for each for the analysis. We defined hyponatremia as a sodium level ≤134 mEq/L, 
and severe hyponatremia as ≤128 mEq/L, in line with previous studies. 5,6 Potentially
predictive variables for hyponatremia tested were: CBZ/OXC serum levels, age, sex
and concomitant AEDs. Clinical characteristics of those hyponatremic were retrieved
from case notes. Symptoms present at the time of hyponatremia, which could not be
explained by another clear cause such as overt AED intoxication or comorbidity were
scored.
Statistics: Sodium levels were modelled either as a continuous variable or as a
dichotomized variable (≤or >134 mEq/L). Independent samples T-Tests for 
continuous variables and 2*2 tables with chi-squared tests for categorical variables
were used to examine the association of the individual risk factors with hyponatremia.
Linear regression was used to assess the relationship of these variables with sodium
levels as a continuous variable in a multivariate analysis. The appropriateness of the
multivariate linear regression was assessed by plotting standardised residuals, which
were visually inspected for normality. Multivariate logistic regression was used to
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assess the relationship of these variables with hyponatremia as a dichotomous
variable.
In people with a sodium level ≤128 mEq/L information on co-medication other than 
AEDs was retrieved from case notes and differences in mean sodium levels between
those using and not using these various medications were analysed with
independent samples T-Tests.
In the subgroup analyses for users of both CBZ and OXC, means of sodium levels
were compared with the paired samples T-Test and the McNemar test was used to
analyze the differences for binary data, such as the occurrence of hyponatremia.
The statistical analysis was carried out on SPSS version 22.0 for Windows (SPSS
Inc., Chicago, IL).
Ethics: The Ethical Committee of UMC Utrecht approved this investigation. All
participants had previously provided written informed consent for data retrieval.
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RESULTS
We identified 1,732 people (94% Caucasians) who had used CBZ (n=1,424) or OXC
(n=358); sodium levels were not measured or not recorded in 361 (21%). Fifty people
in the cohort had sodium levels measured during both CBZ and OXC treatment; no
one used both drugs at the same time. Sodium levels were measured and recorded
in 1,132 (79%) treated with CBZ (616 males) with a mean age of 41.8 ±15.6 (years
±SD) and a mean Na+ level of 138.4 ±4.2 mEq/L. In the OXC group sodium levels
were measured and recorded in 289 people (81%; 150 males), with a mean age of
37.2 ±16.2 and a mean Na+ level of 135.7 ±5.5 mEq/L. The average number of Na+
measurements was 1.71±1.0 (min 1, max 11). Hyponatremia was seen in 26%
(294/1,132) in the CBZ group and 46% (134/289) in the OXC group. Severe
hyponatremia was found in 7% (81/1,132) in the CBZ group and in 22% (65/289) in
the OXC group.
Hyponatremia was symptomatic in 48% (194/402, 26 missing data) of those found to
have low sodium levels (35% in people with mild hyponatremia and 72% in severe
hyponatremia). Among those symptomatic 6% had CBZ or OXC levels above the
therapeutic range (10 with CBZ levels ≥11, one with OXC level ≥35). Symptoms
were mostly mild: dizziness (94/194; 48%), diplopia (48/194; 25%), unsteady gait
(63/194; 32%), lethargy (37/194;19%), cognitive slowness (26/194;13%), tiredness
(71/194;37%) headache (30/194; 15%), nausea and vomiting (34/194;18%). Falls
were reported by 11% (21/194; 11%) and two who had severe hyponatremia
sustained a fracture due to falling. In the group with severe hyponatremia seizure
aggravation was seen in 22% (22/102). Six (3%, 5 with severe hyponatremia) were
admitted to hospital for treatment.
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CBZ/OXC and sodium levels (table 1)
Sodium levels were significantly associated with serum levels of CBZ (p<0.001) and
OXC (p=0.001), but explained only a small part of the variance in the continuous
sodium levels (R2=0.03 and 0.04, respectively, figure 1). Adjustment for age, sex and
number of concomitantly used AEDs did not influence this association. All these
cofactors were independently associated with continuous sodium levels. (suppl fig 1
for age and sodium levels) Mean sodium levels were lower in females (136.9 mEq/L
with CBZ, 133.3 mEq/L with OXC) than in males (137.6 mEq/L with CBZ, 135.4
mEq/L with OXC) (p=0.012 in CBZ and p=0.005 in OXC).
CBZ/OXC and hyponatremia (table 2, table 3)
Serum levels of CBZ and OXC were significantly associated with hyponatremia,
increasing the risk by a factor 1.20 (95% CI 1.12-1.28, p<0.001) and 1.06 (95% CI
1.02-1.10, p=0.001) per unit (mg/L) increase, respectively. This association remained
significant in the multivariate logistic analysis.
When sodium levels were used as a dichotomized variable, sex remained a risk
factor for hyponatremia in the OXC group, but not in the CBZ group. Women in the
OXC group were more likely to develop hyponatremia (55%) than men (39%).
In those over 40 years hyponatremia was seen in 34% (compared with 17% <40
years) in the CBZ group and in 56% (compared with 39% <40 years) in the OXC
group. In a multivariate logistic regression analysis, age over 40 increased the odds
of hyponatremia by a factor 2.5 in the CBZ group and 2.2 in the OXC group.
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The hyponatremia frequency in different age categories for CBZ and OXC users is
shown in supplementary figure 2.
Monotherapy was associated with a lower risk of hyponatremia than polytherapy.
After correction for drug levels, age and sex this association did not reach
significance in the OXC group. The risk of hyponatremia was significantly increased
with increasing number of concomitant AEDs in both groups.
Independent risk factors in both treatment groups were the concomitant use of
clobazam (CLB) and phenytoin (PHT). Valproate (VPA) and phenobarbital (PB) were
additional risk factors for hyponatremia in the CBZ group.
These observations were similar across sodium levels in three categories (≤ 128, 
129-134, ≥ 135) but numbers in the severe hyponatremia group were small (results 
not shown).
Severe hyponatremia and co-medication (table 4)
In those with a sodium level of ≤128 mEq/L (n=146) concomitant use of antidiabetics 
(n=5), NSAIDS (n=20), antipsychotics (n=15), antidepressants (n=10),
antihypertensive drugs (n=25) (especially diuretics (n=4) and ACE inhibitors (n=8))
and proton pomp inhibitors (n=16) was checked. In those treated with OXC,
additional use of antihypertensive drugs and use of co-medication that, as a group,
can influence sodium levels were significantly associated with a lower sodium level.
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Users of CBZ and OXC (table 5)
Sodium levels were measured during CBZ and OXC treatment in 50 individuals who
used the drugs sequentially (64% had CBZ first then had OXC). Mean sodium levels
were significantly lower on OXC (131 mEq/L) when compared to CBZ treatment (135
mEq/L, p<0.001). Hyponatremia was seen more frequently than in the total cohort;
during CBZ use in 40% (20/50) and during OXC use in 68% (34/50). The risk of
hyponatremia on CBZ was significantly associated with the risk of hyponatremia on
OXC within this group (p=0.001). Eighteen of the 20 who had hyponatremia on CBZ
also developed hyponatremia on OXC. The remaining two were mildly hyponatremic
(≥132 mEq/l).
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DISCUSSION
CBZ and OXC are widely used but physicians should be aware of the high
prevalence of COIH. We have seen a relatively high frequency of severe
hyponatremia, especially in those treated with OXC. We checked potential co-
medication that might also trigger hyponatremia. People who were on
antihypertensives had a significantly lower mean sodium level in the OXC group.
Only 3% (2/58) of this group used diuretics and 14% antihypertensives (including
diuretics) compared with 24% use of diuretics in another study with a larger cohort of
OXC treated people and a lower prevalence (11%) of severe hyponatremia.6 Co-
medication does not seem to explain the higher prevalence of severe hyponatremia
in the OXC group.
The rate of COIH was higher in the elderly and this was in line with previous reports.5-
7 The odds of hyponatremia were doubled in people over the age of 40 years. Thirst
sensation, renal function, urine concentrating abilities and hormonal modulators of
salt and water balance are often impaired in the elderly, which makes older people
more susceptible to COIH.8 In a previous study5 a much stronger age effect was
reported in the OXC treated group than in those treated with CBZ but the sample was
smaller. We found that the age effect was comparable in both groups.
The subgroup analysis of those who used CBZ and subsequently OXC suggests that
an individual with hyponatremia associated with CBZ is also likely to develop
hyponatremia while taking OXC. In an individual who does not develop hyponatremia
with CBZ, there is a 53% chance of hyponatremia if subsequently OXC is used. The
underlying mechanisms are likely to be similar but seem apparently more efficient
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when OXC is used. This analysis also implies that a subset of people may be
genetically predisposed to COIH.
Our findings suggest that women seem to be at higher risk of developing
hyponatremia if taking OXC. In the CBZ group being female was a risk factor in the
linear regression analysis, but with a very small effect size. COIH is probably caused
by antidiuresis where CBZ and OXC are thought to stimulate the vasopressin water
reabsorption pathway.9 The AVPR2 gene, coding for the vasopressin 2 receptor
(V2R) which plays a key role in water reabsorption, is located on the X chromosome
in a region (Xq28) with high probability of escape from inactivation.10 Escape from
inactivation results in higher expression of levels of transcript in females.11,12 This
provides a possible explanation for why women are at a higher risk of hyponatremia,
especially with the use of drugs that stimulate V2R. The underlying mechanisms
seem to be more susceptible to OXC possibly through a stronger effect of OXC,
compared with CBZ, on V2R. The use of OXC could therefore have a larger influence
in women.
In a larger cohort study on OXC induced hyponatremia a sex difference was not
found but within this cohort the mean age was 15 years higher than the mean age in
our OXC cohort.6 The effect of impaired renal function at older age on the COIH risk
was stronger in this study than the effect of sex difference. So in an older cohort this
sex effect could be missed. Perhaps also the difference in ethnic background plays a
role. Previous studies reported conflicting results regarding the association between
CBZ and OXC dose and hyponatremia. Some smaller studies did find a dose
response relationship,13-16 but larger studies could not confirm this.5,6 We found a
significant relationship between CBZ and OXC drug levels and hyponatremia, but the
effect size was small. This might explain why this was not seen in some other
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studies. Staying below the ‘mean relatively safe drug level’ (7.4 mg/L for CBZ and
18.7 mg/L for OXC) might lower the need to withdraw these drugs due to
hyponatremia.
We found that concomitant use of CLB and PHT in both groups and VPA and PB in
the CBZ group may increase the risk of hyponatremia. The diuretic response to a
water load was previously tested and found to be significantly greater in those taking
carbamazepine and phenytoin in combination than in those on carbamazepine
monotherapy17; this may explain our finding. Concomitant use of VPA and PB were
also previously described as risk factors for CBZ induced hyponatremia.7 A previous
study suggested OXC in combination with levetiracetam (LEV) was a risk factor5, but
we found that concomitant use of LEV did not influence hyponatremia risk in either
group.
One limitation of this study is that there were no recorded sodium levels for a fifth of
the cohort. This, however, may reflect clinical practice in which some people, due to
pressure of time and dislike of venipuncture, do not have samples taken for assay.
The study was conducted at a single tertiary referral centre and it is likely that levels
were estimated more frequently than in the primary or secondary levels of care.
It is important for clinicians to be aware of the high prevalence of COIH and
nonspecific symptoms. Mild to moderate COIH may cause lethargy, cognitive
slowness, headache, dizziness and nausea. Severe COIH may lead to falls, seizure
aggravation and hospitalization.6,9 We found mild symptoms in almost half of those
with hyponatremia although due to the design we used we can’t be certain if these
symptoms were due to hyponatremia or if another cause, such as high AED levels
could be playing a role. Of interest, is that only 6% of the symptomatic had high
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levels of either CBZ or OXC at the time. We have not systematically collected data on
levels of other concomitant AEDs or of metabolites of CBZ and OXC.
A recent population-based study found that CBZ use compared to no antiepileptic
use was associated with a 8.2 higher relative risk of hospitalization with hyponatremia
within 30 days of drug initiation in people over 65 years.18 To prevent this, physicians
should have a low threshold of suspicion for this common adverse effect and
checking sodium levels should be routine in clinical practice for people taking either
of these drugs. Mild hyponatremia can be treated with fluid restriction; in case of
severe hyponatremia we would recommend the introduction of an alternative
antiepileptic drug with the gradual withdrawal of either CBZ or OXC. Alternative
antiepileptic medication also needs to be considered especially in the elderly,
females and in those on multiple AEDs, before hyponatremia develops. Prospective
studies are warranted to establish the true frequency of symptomatic hyponatremia.
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FIGURE LEGENDS
Fig 1.
Sodium levels in relation to drug levels and age
Relationship between sodium level (Na+ mEq/L) and drug level (mg/L) and
relationship between sodium level and age (years) within both the carbamazepine
(CBZ) and oxcarbazepine (OXC) treatment group.
SUPPLEMENTARY FIGURE LEGENDS
Suppl. fig 1.
Mean sodium levels in different age categories for carbamazepine and
oxcarbazepine users.
Suppl. fig 2.
Hyponatremia frequency in different age categories for carbamazepine and
oxcarbazepine users.
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Regr. coeff= regression coefficient.
NcoAED= number of concomitant AEDs used. * reference group= female
TABLES
Table 1. Univariate and multivariate analysis of demographic and clinical data with sodium level (mEql/l) as dependent
variable.
Univariate Analysis Multivariate Analysis
carbamazepine oxcarbazepine carbamazepine oxcarbazepine
N R2
Regr.
coeff
P-value N R2
Regr.
coeff
P- value
Regr.
coeff
P- value
Regr.
coeff
P- value
drug level
(mg/L)
1,008 0.025 -0.34 <0.001 257 0.039 -0.17 0.001 -0.31 <0.001 -0.19 <0.001
age
(years)
1,132 0.078 -0.09 <0.001 289 0.040 -0.08 0.001 -0.08 <0.001 -0.06 0.007
sex* 1,132 0.006 0.76 0.010 289 0.027 2.11 0.005 0.91 0.002 2.30 0.003
NcoAEDs 1,087 0.018 -0.77 <0.001 277 0.054 -1.81 <0.001 -0.64 <0.001 -1.32 0.005
n=968 R²=0.116 n=245 R²=0.135
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Table 2. Univariate analyses of demographic and clinical data with hyponatremia (Na ≤ 134 mEq/L) as 
dependent variable.
AgeCat40 = age category split at 40 years; CLB=clobazam, PHT= phenytoin, VPA= valproic acid, PB=
phenobarbital,
carbamazepine oxcarbazepine
na< =134 na>134 p-value na< =134 na>134 p-value
mean drug level
(mg/L) 8.3 7.4 <0.001 21.7 18.7 0.001
mean age (yrs) 49.1 39.3 <0.001 40.6 34.3 0.001
AgeCat40 ≤ 40 88 (17%) 440 (83%) <0.001 64 (39%) 101 (61%) 0.003
>40 206 (34%) 398 (66%) 70 (56%) 54 (44%)
sex m 152 (25%) 464 (75%) 0.28 58 (39%) 92 (61%) 0.006
f 142 (28%) 374 (72%) 76 (55%) 63 (45%)
monotherapy yes 53 (17%) 260 (83%) <0.001 29 (36%) 52 (64%) 0.03
no 230 (30%) 544 (70%) 99 (51%) 97 (49%)
CLB yes 56 (42%) 80 (59%) <0.001 31 (70%) 13 (30%) <0.001
no 227 (24%) 724 (76%) 97 (42%) 136 (58%)
PHT yes 34 (38%) 56 (62%) 0.008 17 (77%) 5 (23%) 0.002
no 249 (25%) 748 (75%) 111 (44%) 144 (56%)
VPA yes 90 (31%) 197 (69%) 0.02 28 (44%) 35 (56%) 0.73
no 193 (24%) 607 (76%) 106 (47%) 120 (53%)
PB yes 22(38%) 36(62%) 0.03 5 (71%) 2 (29%) 0.18
no 261(25%) 768(75%) 129 (46%) 153 (54%)
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Table 3. Multivariate logistic regression analysis of demographic and clinical data with hyponatremia
as dependent variable
carbamazepine (n=968) oxcarbazepine (n=245)
Odds
Ratio
95% C.I.
P-value
Odds
Ratio
95% C.I.
P-value
Lower Upper Lower Upper
drug level (mg/L) 1.23 1.14 1.315 <0.001 1.08 1.04 1.12 <0.001
age (years) 1.04 1.03 1.05 <0.001 1.03 1.01 1.04 0.004
sex* 1.29 0.95 1.76 0.11 2.25 1.29 3.93 0.004
NcoAEDs 1.45 1.22 1.73 <0.001 1.98 1.13 2.26 0.008
AgeCat>40a 2.51 1.83 3.45 <0.001 2.24 1.28 3.90 0.004
monotherapyb 0.43 0.30 0.62 <0.001 0.64 0.35 1.16 0.14
VPAb 1.82 1.29 2.58 0.001 1.20 0.64 2.27 0.57
PBb 1.98 1.075 3.66 0.03 3.27 0.53 20.18 0.20
CLBb 2.41 1.57 3.68 <0.001 3.84 1.75 8.41 0.001
PHTb 2.40 1.43 4.01 0.001 6.30 2.04 19.43 0.001
NcoAEDs = number of concomitant antiepileptic drugs; AgeCat>40 =age category above 40 years;
* reference group= male
a Model with covariates: drug level, sex and NCoMed
b Each therapy is separately tested in a model with covariates: drug level, age and sex
Levetiracetam, lamotrigine, lacosamide, topiramate, gabapentin, clonazepam, vigabatrin and ethosuximide
were not significantly associated with hyponatremia in a multivariate analysis.
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Table 4. The effect of non-AED co-medication in severe CBZ and OXC induced hyponatremia
(Na≤128 mEq/L).  
a No data on co-medication was available for 13 people.
carbamazepine oxcarbazepine
Comedication mean Na+ Na P-value mean Na+ Na P-value
Antihypertensive drugs no 125.13 56 0.29 125.69 52 0.001
yes 126.00 17 121.88 8
Diuretics no 125.35 71 0.69 125.34 58 0.03
yes 124.50 2 120.50 2
ACE inhibitors no 125.22 67 0.32 125.34 58 0.03
yes 126.50 6 120.50 2
No comedication no 125.42 33 0.81 124.21 24 0.04
yes 125.25 40 125.83 36
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Table 5. Hyponatremia in subgroup using both carbamazepine and oxcarbazepine sequentially.
Oxcarbazepine Total
Na≤134 Na>134
Carbamazepine Na≤134 N 18 2 20
% within Na≤134 90,0% 10,0%
Na>134 N 16 14 30
% within Na≤134 53,3% 46,7%
Total 34 16 50
McNemar test: p= 0.001
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Key points
 Hyponatremia was seen in a quarter of those taking carbamazepine (CBZ)
and in almost half on oxcarbazepine (OXC).
 Age over 40 years, high levels of CBZ and OXC and concomitant use of other
antiepileptic drugs were risk factors for CBZ and OXC induced hyponatremia.
 Females on OXC were at a higher risk of hyponatremia than males.
 The risk of hyponatremia on CBZ was significantly associated with the risk of
hyponatremia on OXC within a subgroup that used both drugs subsequently.
 Regular sodium level assays in those taking CBZ or OXC are recommended
and results should be acted upon.
